Last reviewed · How we verify
Early sequential nephron blockade
Early sequential nephron blockade is a therapeutic strategy that sequentially inhibits multiple points in the renin-angiotensin-aldosterone system (RAAS) to reduce renal injury and proteinuria.
Early sequential nephron blockade is a therapeutic strategy that sequentially inhibits multiple points in the renin-angiotensin-aldosterone system (RAAS) to reduce renal injury and proteinuria. Used for Chronic kidney disease with proteinuria, Diabetic nephropathy.
At a glance
| Generic name | Early sequential nephron blockade |
|---|---|
| Sponsor | University of Parma |
| Drug class | RAAS inhibitor combination strategy |
| Target | Renin-angiotensin-aldosterone system (multiple targets) |
| Modality | Small molecule |
| Therapeutic area | Nephrology / Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
This approach combines agents that block different steps of the RAAS pathway—typically starting with ACE inhibitors or ARBs, followed by aldosterone antagonists and/or direct renin inhibitors—to achieve more complete suppression of the system. By blocking the RAAS at multiple sequential sites early in disease progression, the strategy aims to prevent progressive nephron loss and slow the decline of renal function in chronic kidney disease.
Approved indications
- Chronic kidney disease with proteinuria
- Diabetic nephropathy
Common side effects
- Hyperkalemia
- Hypotension
- Acute kidney injury
Key clinical trials
- Early Sequential Nephron Blockade in Acute Heart Failure Patients: A Randomised, Controlled Study (PHASE3)
- Sequential Nephron Blockade in Acute Heart Failure (PHASE3)
- Safety and Efficacy of Early, seQUential Oral dIuretic Nephron blockAde In Acute Heart Failure (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |